GU Cancers 2018 | SPARTAN vs. PROSPER: apalutamide or enzalutamide for nmCRPC?

Eric Small • 8 Feb 2018

GU Cancers 2018

Genitourinary Cancer Prostate Cancer Apalutamide Enzalutamide

PROSPER SPARTAN

With exciting data from the Phase III SPARTAN (NCT01946204) and PROSPER (NCT02003924) trials of apalutamide and enzalutamide, respectively, for the treatment of nonmetastatic castration-resistant prostate cancer (nmCRPC), a question arising is which drug is better. Speaking from the 2018 Genitourinary Cancers Symposium, in San Francisco, CA, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses this question.

Nonmetastatic CRPC: meeting an unmet need

Eric Small • 8 Feb 2018

Straightforward study design: SPARTAN trial of apalutamide for nmCRPC

Eric Small • 8 Feb 2018

This is SPARTAN! Apalutamide treatment for nmCRPC

Eric Small • 8 Feb 2018

How will the results of the SPARTAN study impact US clinical practice in prostate cancer?

Eric Small • 8 Feb 2018

Related Videos

ABACUS trial: preoperative atezolizumab in urothelial carcinoma

Thomas Powles • 19 Jun 2018

Renal cell carcinoma trial analysis: current landscape of immunotherapy combinations

Toni Choueiri • 9 Nov 2018

Awaiting key results for enzalutamide and apalutamide in nmCRPC

Simon Crabb • 29 Nov 2018

Why attend a medical congress: a patient and student perspective

Max Williamson • 29 Nov 2018